Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Befotertinib with Rifampicin or Itraconazole in Healthy Participants
NCT07809815Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of befotertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve from time 0 to the last measurable concentration and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07809815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809815.